Table 5.

Summary of Antiviral Drug Clinical Trials for COVID-19

Number	TrialID	Intervention	Study Design	Target Size	Primary Outcome Result	Reference
1	ChiCTR2000029600	Favipiravir	Control Open-Label	80	A shorter viral clearance time was found for the FPV arm versus the control arm.	[25]
2	ChiCTR2000030254	Favipiravir; Arbidol	Randomized, controlled, open-label	240	Clinical recovery rate of Day 7 does not significantly differ between Favipiravir group and Arbidol group.	[26]
3	NA	Arbidol; Lopinavir/ritonavir	Control	50	Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group.	[27]
4	ChiCTR2000029308	Lopinavir-Ritonavir	Randomized, controlled open-label	199	Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement	[28]
5	NCT04276688	Beta-1b, lopinavir–ritonavir, and ribavirin	Randomized Open-label,	127	The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab than the control group.	[29]
6	NCT04257656	Remdesivir	Randomized, Double-blind, Placebo-controlled	237	Remdesivir use was not associated with a difference in time to clinical improvement.	[30]